高瓴 大调仓

Group 1: Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported its US stock holdings as of the end of Q4 2025, with a focus on Chinese concept stocks, which constitute 92% of its portfolio [1][2]. - The top ten holdings of HHLR include Pinduoduo, Alibaba, BeiGene, Futu Holdings, Legend Biotech, Arrivent Biopharma, Beike, Webull Corp, Cytek Biosciences, and Clearwater Analytics, with seven of these being Chinese concept stocks [2][4]. Group 2: Investment Actions - HHLR significantly increased its holdings in Pinduoduo and Alibaba, while reducing its positions in Futu Holdings and Webull, indicating a strategic shift towards e-commerce leaders, biomedicine, and technology sectors [1][5][7]. - As of the end of Q4 2025, HHLR held 10.72 million shares of Pinduoduo, an increase of 2.13 million shares from the previous quarter, and 5.43 million shares of Alibaba, up by 2.14 million shares [5][7]. Group 3: Market Trends and Sector Focus - The investment in Pinduoduo aligns with similar moves by other major private equity firms, suggesting a consensus on the stock's potential despite a recent decline in its share price [5]. - HHLR also showed interest in technology stocks, acquiring shares in Google and TSMC, reflecting a broader trend of investment in AI and semiconductor sectors, which are seen as having significant growth potential [8][10].